| Literature DB >> 31485363 |
Hany S Hamza1, Magdy Moussa2, Abdelrahman M Elhusseiny1,3.
Abstract
PURPOSE: To report a rare case of melanocytoma associated choroidal neovascularization (CNV) treated with intravitreal aflibercept.Entities:
Year: 2019 PMID: 31485363 PMCID: PMC6702810 DOI: 10.1155/2019/2672798
Source DB: PubMed Journal: Case Rep Ophthalmol Med
Figure 1(a) Fluorescein angiography of the left eye showing early hyperfluorescence in the temporal juxtapapillary region. (b) Fundus photography of the left eye.
Figure 2(a) Optical coherence tomography (OCT) showing diffuse macular thickening. (b) OCT showing complete resolution of the macular edema.
Review of previous reports on melanocytoma associated choroidal neovascularization (CNV).
| Case | Chalam [ | Tran [ | Kamisasaku [ | Al-Halafi [ | Batmanabane et al. [ | Urrets-Zavalia [ | Rodrigues [ | Current case |
|---|---|---|---|---|---|---|---|---|
| Age | Middle age | 45 years | 63 years | 45 years | 28 years | 50 years | 49 years | 51 years |
|
| ||||||||
| Gender | Male | - | Male | Male | Female | Male | Female | Male |
|
| ||||||||
| Affected eye | Right | left | Left | Right | Left | Right | Left | Left |
|
| ||||||||
| Primary presentation | Diminution of vision | Diminution of vision | Diminution of vision | Diminution of vision | Diminution of vision | Diminution of vision | Diminution of vision | Diminution of vision |
|
| ||||||||
| Visual Acuity at 1st presentation | 20/200 | 20/100 | 0.9 LogMAR | 20/160 | 20/40 | 20/80 | Counting fingers 50 cm | 20/200 |
|
| ||||||||
| Location of choroidal neovascularization | Juxtafoveal | Peripapilla y | Adjacent to optic disc | Juxtafoveal | Peripapillary extending to the macula | Peripapillary | Macular | Peripapillary |
|
| ||||||||
| Treatment | Photodynamic therapy | Vitrectomy and submacular surgery | Intravitreal Bevacizumab (3 injections) | Intravitreal Bevacizumab (1 injection) | Intravitreal Ranibizumab (1 injection) | Intravitreal Bevacizumab | Intravitreal anti-VEGF was recommended | Intravitreal Aflibercept (3 injections) |
|
| ||||||||
| Follow-up | 6 months | 14 months | 12 months | 12 months | 6 months | 36 months | Lost to follow- | 13 months |